Hydrochlorothiazide
- Product NDC
- 68071-4176
- Requested package NDC
- 68071-4176-6
- 11-digit product format
- 680714176
- Labeler code
- 68071
- Product ID
- 68071-4176_bb64231a-3b27-3c15-e053-2a95a90ad079
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Hydrochlorothiazide
- Dosage form
- CAPSULE, GELATIN COATED
- Route
- ORAL
- Labeler
- NuCare Pharmaceuticals,Inc.
- Application
- NDA020504
- Marketing category
- NDA AUTHORIZED GENERIC
- Marketing start
- 1996-12-27
- Marketing end
- 0000-00-00
- Substance
- HYDROCHLOROTHIAZIDE
- Active strength
- 13 mg/1
- Pharmacologic classes
- Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [CS]
- NDC exclude flag
- No
- Listing certified through
- 2022-12-31
- Current FDA listing
- Historical FDA.report record
NDC auxiliary status#
Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded package | package | 68071-4176 | 68071-4176-6 | D | Discontinued by firm | 2026-07-31 |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N020504-001 | MICROZIDE | HYDROCHLOROTHIAZIDE | 12.5MG | CAPSULE / ORAL | AB | RLD, RS | 1996-12-27 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N020504-001 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N020504-001 | MICROZIDE | 12.5MG | CAPSULE / ORAL | AB | RLD, RS | 1996-12-27 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N020504-001 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | QPharma, Inc. | 5bacc909-6b02-4815-85ef-55fd25b1b1f7 | 2025-12-05 | Warnings, Adverse reactions | 020504 NDA020504 |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | Actavis Pharma, Inc. | a3eb7294-f913-434b-896c-da028bfebc73 | 2024-08-01 | Warnings, Adverse reactions | 020504 NDA020504 |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | Proficient Rx LP | c1052d38-fd75-40c2-a685-0e889009be0b | 2023-02-01 | Warnings, Adverse reactions | 020504 NDA020504 |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | Aphena Pharma Solutions - Tennessee, LLC | 0f7a608d-748b-49a9-a4b3-b3fdcab53ce0 | 2017-12-21 | Warnings, Adverse reactions | 020504 NDA020504 |
FDA-Initiated Inactive NDC Indexing#
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 68071-4176-6 | 68071417606 | 60 CAPSULE, GELATIN COATED in 1 BOTTLE (68071-4176-6) | 2017-12-06 | 0000-00-00 | No | No | Current |